Reviewer’s report

Title: Macular and optic disc edema and retinal vascular leakage in familial amyloid polyneuropathy with a transthyretin Val30Met mutation: a case report

Version: 1 Date: 10 March 2014

Reviewer: Tatjana Josifova

Which of the following best describes what type of case report this is?: Unreported or unusual side effects or adverse interactions involving medications

Has the case been reported coherently?: Yes

Is the case report authentic?: Yes

Is the case report ethical?: Yes

Is this case worth reporting?: Yes

Is the case report persuasive?: No

Does the case report have explanatory value?: No

Does the case report have diagnostic value?: No

Will the case report make a difference to clinical practice?: Yes

Is the anonymity of the patient protected?: Yes

Comments to authors:

Laboratory results considering the liver function are not given in the study.

Only the past history medication could not be relevant for the recent statues and cannot exclude the probability of retinal changes due to medication at present.

The FA findings on fig. 1 do not exactly show a leakage of the small capillary vessels. A combination of staining and leakage could be detected parafoveal. On the other hand the OCT findings showing an advanced CMS -subfoveal do not match at all with the FA findings. It's very unlogical that the advanced intraretinal and subretinal CME seen at the OCT findings is not present at the FA findings.

Fig. 3 showing the FA of the right eye do not exactly present an optic nerve edema, but it shows a pulling of the dye at the edges of the optic nerve.

The further recommended treatment of the right eye at this stage of the
"changes" is not necessary since no ME or ischemic retinal changes are detected on the FA or OCT results. Moreover the recommended LPP does not explain the treatment modality (focal or panretinal) LPP.

It is not clear why does the initial treatment of the left eye include only two injections of intravitreal anti-VEGF therapy when the recommended up-loading dosage always includes three injections application. No OCT results are presented after the second injection to show that two injections were enough for a successful therapy.

**Declaration of competing interests:**

I declare that I have no competing interests